Candidate Compounds Covid19

Version vom 22. Juni 2020, 10:27 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.

• reviews on covid drug development
• scouting ideas

• Patients on biologicals
• HMGB1, RAGE
• pre-Interleukin 6
• post-Interleukin 6
• pre-TNFalpha
• post-TNFalpha
• pre-Interleukin 17
• post-Interleukin 17
• pre-Interleukin 1
• post-Interleukin 1
• Inflammasome colchicine
• other anti-inflammatory
• NK-kappaB
• STAT 3
• JAK Janus Kinase
• Corticosteroids
• Cytokine absorbers
• Target Complement system
• Target Extracellular traps
• Anticoagulant in covid19
• Antioxidants
• Stem cells
• MDSC cells
• Interferons

• other single compounds
• Retargeted single compounds
• Hydroxychloroquine
• Target ACE2, Spike protein
• Target TMPRSS2, Spike protein any other covid targed herein
• other antiviral compounds
• AV Remdesivir
• AV Lopinavir
• AV Ivermectin

• Vitamin D
• Anorganic nutrients Magnesium
• Anorganic nutrients Selenium
• Anorganic nutrients Zinc
• Nutrition, general
• Exercise, Vibration

• Traditional Chinese Medicine
• Natural compounds

• Statins
• Antidiabetic compounds, any
• RSP - On RAS drugs

• Reconvalescent blood products, Passive vaccine
• Plasmapheresis

• Immunodeviation e.g. by adjuvants or other vaccinations
• Radiation therapy
• Phototherapy
• Active vaccine

007

32401466 2006. Remdesivir
32401463 2006. Favipiravir
32496248 2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.
32496246 2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.
32496241 2020. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?
32393681 2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab.
32468742 2020. Reply: Vitamin C as a Possible Therapy for COVID-19.
32410417 2020. Vitamin C as a Possible Therapy for COVID-19.
32476308 2020. Empirical Treatment and Prevention of COVID-19.
32466136 2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.
32455961 2020. Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals: A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel.
32486229 2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.
32481690 2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.
32471278 2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
32471205 2020. Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
32455534 2020. Potential Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds.
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32429099 2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32463348 2020. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
32463308 2020. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
32392184 2020. Clinical trials for COVID-19 should include sex as a variable.
32456123 2020. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
32474406 2020. The rediscovery of hydroxychloroquine in allergic diseases in the COVID-19 era.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.
32451353 2020. Evidence of Protective Effect of Hydroxychloroquine on COVID-19.
32423974 2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?
32393664 2020. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.
32475851 2020. COVID-19: Stay Cool toward Corticosteroids.
32475104 2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.
32293020 2020. Palliativ farmakologisk behandling vid svar covid-19.
32444382 2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
32442946 2020. inverted question markBCG versus COVID-19?
32442941 2020. Hidroxicloroquina. Mensajes desde la cardiologia en tiempos de pandemia por coronavirus.
32490889 2020. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
32397399 2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
32162896 2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.
32407051 2020. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19?
32485894 2020. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
32455942 2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.
32429580 2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
32408547 2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
32486364 2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.
32495926 2020. Does amantadine have a protective effect against COVID-19?
32397511 2020. 25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.
32486488 2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
32471251 2020. Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis.
32438620 2020. COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.
32492809 2020. Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" Nutrients 2020, 12(4), 988.
32492787 2020. Reply: "Vitamin D Supplementation in Influenza and COVID-19 Infections. Comment on: Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths Nutrients 2020, 12(4), 988".
32418757 2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?
32471171 2020. Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells.
32423027 2020. COVID-19: An Update About the Discovery Clinical Trial.
32423024 2020. The Rationale for Potential Pharmacotherapy of COVID-19.
32434254 2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.
32470046 2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light.
32497149 2020. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.
32505040 2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.
32491112 2020. Does Vitamin D play a role in the management of Covid-19 in Brazil?
32381590 2020. Ethics of controlled human infection to address COVID-19.
32472653 2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
32472939 2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.
32448818 2020. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
32447783 2020. Convalescent plasma for COVID-19: Back to the future.
32449169 2020. How did we rapidly implement a convalescent plasma program?
32449171 2020. COVID-19: are neutralizing antibodies neutralizing enough?
32428966 2020. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains.
32395792 2020. COVID-19: Main therapeutic options.
32507409 2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
32442105 2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.
32397182 2020. Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.
32486283 2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
32397643 2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.
32464700 2020. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.
32485102 2020. Current Perspective of Antiviral Strategies against COVID-19.
32369098 2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).
32398379 2020. Convalescent plasma for patients with COVID-19.
32398378 2020. Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19.
32398377 2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.
32438839 2020. Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?
32462848 2020. Interleukine-1 et blocage du COVID-19.
32348059 2020. COVID-19, dans les brouillards de l'hydroxychloroquine (4).
32320161 2020. Covid-19, dans les brouillards de l'hydroxychloroquine (3).
32495979 2020. Emergence of novel coronavirus and progress toward treatment and vaccine.
32512588 2020. Challenges in the Production of Convalescent Hyperimmune Plasma in the Age of COVID-19.
32453251 2020. Extracorporeal Hemoadsorption: An Option for COVID-19 Associated Cytokine Storm Syndrome.
32496422 2020. Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis.
32500793 2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.
32380908 2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
32510799 2020. The Application Of Plasmapheresis For Covid-19 Patients.
32501607 2020. Selective C-reactive protein (CRP) apheresis for Covid-19 patients suffering from organ damage.
32433189 2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.
32402475 2020. Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data.
32473596 2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
32491199 2020. Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.
32500936 2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
32400382 2020. [Brug af hydroxychloroquin til COVID-19].
32400380 2020. [Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection].
32391669 2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].
32391667 2020. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].
32391659 2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].
32458599 2020. [Pharmacological characteristics of chloroquine and suggestions for its use in treatment of coronavirus disease 2019 (COVID-19)].
32489024 2020. [Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors].
32450629 2020. [Application of convalescent plasma therapy on novel coronavirus infection].
32034899 2020. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].
32023685 2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
32075365 2020. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].
32057209 2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].
32397700 2020. [Analysis of application of herd immunity as a control strategy for COVID-19].
32388937 2020. [Real-world efficacy and safety of lopinavir/ritonavir and arbidol in treating with COVID-19 : an observational cohort study].

32473600 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
32491981 2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.
32487283 2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.
32490731 2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.
32432977 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
32403995 2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
32496239 2020. Potential pharmacological agents for COVID-19.
32496238 2020. COVID-19 vaccine development and the way forward.
32496237 2020. AYUSH for COVID-19: Science or Superstition?
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
32436995 2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
32436994 2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
32510105 2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.
32476594 2020. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
32462719 2020. Nutrition Therapy in Critically Ill Patients with Coronavirus Disease (COVID-19).
32505467 2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
32505245 2020. COVID-19 vaccine development pipeline gears up.
32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
32512490 2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19.
32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
32460209 2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
32512493 2020. The effects of allium sativum on immunity within the scope of COVID-19 infection.
32454510 2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.
32492996 2020. Management of nutritional consultations in local clinics during SARS-CoV-2 pandemic.
32492298 2020. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence.
32492293 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.
32506067 2020. Covid-19 and Exercise-Induced Immunomodulation.
32446287 2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.
32468635 2020. Food as medicine: a possible preventive measure against coronavirus disease (COVID-19).
32442323 2020. Curcumin as a potential treatment for COVID-19.
32430996 2020. Potential effects of curcumin in the treatment of COVID-19 infection.
32424845 2020. Artemisia annua: Trials are needed for COVID-19.
32503877 2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
32510169 2020. A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19.
32501538 2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
32492211 2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.
32492210 2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion.
32492205 2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.
32492200 2020. Remdesivir and Tocilizumab: Mix or Match.
32484930 2020. Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients.
32484915 2020. Feasibility of Tocilizumab in ICU patients with COVID-19.
32421836 2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.
32496442 2020. Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?
32490532 2020. HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern.
32506862 2020. Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients.
32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.
32427277 2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
32495940 2020. Probiotics and COVID-19: is there any link?
32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
32505910 2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.
32502901 2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.
32498009 2020. Mass intake of hydroxychloroquine or chloroquine in the present context of the Covid-19 outbreak: Possible consequences in endemic malaria settings.
32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.
32463026 2020. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
32506110 2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
32459919 2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
32369285 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369284 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369283 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369282 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32369281 2020. A Trial of Lopinavir-Ritonavir in Covid-19.
32412709 2020. Compassionate Use of Remdesivir in Covid-19. Reply.
32412708 2020. Compassionate Use of Remdesivir in Covid-19.
32412707 2020. Compassionate Use of Remdesivir in Covid-19.
32412706 2020. Compassionate Use of Remdesivir in Covid-19.
32412705 2020. Compassionate Use of Remdesivir in Covid-19.
32438383 2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.
32325475 2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.
32472069 2020. Questions remain following first COVID-19 vaccine results.
32393915 2020. Biggest COVID-19 trial tests repurposed drugs first.
32417850 2020. Drug researchers pursue new lines of attack against COVID-19.
32415300 2020. Biotech companies prepare for COVID-19 downturn.
32415251 2020. 15 drugs being tested to treat COVID-19 and how they would work.
32488217 2020. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
32382072 2020. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.
32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
32415276 2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.
32409766 2020. Dozens of coronavirus drugs are in development - what happens next?
32405023 2020. Coronavirus drugs trials must get bigger and more collaborative.
32203367 2020. Coronavirus vaccines: five key questions as trials begin.
32512579 2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.
32504019 2020. The coronavirus outbreak could make it quicker and easier to trial drugs.
32424192 2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.
32273621 2020. If a coronavirus vaccine arrives, can the world make enough?
32299148 2020. Considerations for Obesity, Vitamin D, and Physical Activity Amid the COVID-19 Pandemic.
32324363 2020. [A szerzett hosszu-QT-szindroma veszelye a koronavirus-jarvany idejen. Fokuszban a hidroxiklorokin]
32324361 2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]
32427644 2020. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
32398330 2020. A Call for Pediatric COVID-19 Clinical Trials.
32423342 2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
32393419 2020. Recent advances of therapeutic targets and potential drugs of COVID-19.
32476189 2020. SARS-CoV-2 pandemic and Vitamin D deficiency-A double trouble.
32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.
32501634 2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?
32488956 2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?
32496926 2020. Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.
32439730 2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?
32295814 2020. Hydroxychloroquine and covid-19.
32116200 2020. COVID-19: Perspectives on the Potential Novel Global Threat.
32472681 2020. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease.
32385052 2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
32381697 2020. The race is on for antibodies that stop the new coronavirus.
32381692 2020. Combination prevention for COVID-19.
32393526 2020. A strategic approach to COVID-19 vaccine R&D.
32385100 2020. Rapid COVID-19 vaccine development.
32461212 2020. Reducing transmission of SARS-CoV-2.
32385101 2020. Rapid repurposing of drugs for COVID-19.
32327575 2020. NIH organizes hunt for drugs.

32409439 2020. Practical aspects of targeting IL-6 in COVID-19 disease.
32409433 2020. Antivirals for COVID-19.
32456769 2020. Early tocilizumab treatment could improve survival among COVID-19 patients.
32456767 2020. Anakinra in COVID-19 therapy: what have we learned from adult-onset Still's disease?
32452345 2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart.
32490931 2020. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.
32444482 2020. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis.
32409522 2020. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis.
32420637 2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
32294756 2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.
32441894 2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.
32438473 2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.
32437587 2020. COVID-19 vaccines: knowing the unknown.
32460358 2020. The early landscape of COVID-19 vaccine development in the UK and rest of the world.
32496938 2020. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.
32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
32512383 2020. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy.
32448039 2020. In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.
32448098 2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
32448034 2020. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches.
32448085 2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
32452282 2020. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.
32431217 2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.
32419646 2020. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study.
32410504 2020. Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study.
32396767 2020. Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations.
32469418 2020. Evaluation of potential therapeutic options for COVID-19.
32445400 2020. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?
32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
32437001 2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".
32434282 2020. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
32472779 2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?
32508069 2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.
32470199 2020. Metformin use amid coronavirus disease 2019 pandemic.
32470160 2020. Glucocorticoid therapy delays the clearance of SARS-CoV-2 RNA in an asymptomatic COVID-19 patient.
32470146 2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis.
32462717 2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
32458475 2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.
32458488 2020. Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.
32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.
32441786 2020. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old.
32437024 2020. Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.
32437019 2020. Baricitinib: A chance to treat COVID-19?
32437014 2020. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19.
32463459 2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.
32492084 2020. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
32428941 2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.
32498081 2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
32474918 2020. An open label cluster randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19 (ARCHAIC) - Protocol publication.
32500556 2020. Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection.
32499314 2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
32449669 2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.
32432527 2020. Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence.
32495917 2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.
32495916 2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report.
32495848 2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
32380868 2020. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
32406282 2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces.
32427004 2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?
32452701 2020. An up-to-date overview of computational polypharmacology in modern drug discovery.
32442040 2020. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.
32447996 2020. Treatments in the COVID-19 pandemic: an update on clinical trials.
32475183 2020. Does lopinavir measure up in the treatment of COVID-19?
32348165 2020. Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.
32282262 2020. Treatment considerations for coronavirus (COVID-19).
32469280 2020. COVID-19: Gene Transfer to the Rescue?
32423245 2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.
32212981 2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.
32501133 2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?
32503817 2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.
32503815 2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
32503814 2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32468014 2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).
32401694 2020. Flying by the seat of our pants: is low dose radiation therapy for COVID-19 an option?
32474476 2020. Risk of using hydroxychloroquine as a treatment of COVID-19.
32468508 2020. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol.
32310670 2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.
32473020 2020. Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial.
32457980 2020. Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.
32443151 2020. Lopinavir pharmacokinetics in COVID-19 patients.
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
32469279 2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.
32469265 2020. Docking study of Chloroquine and Hydroxychloroquine interaction with SARS-CoV-2 spike glycoprotein-An in silico insight into the comparative efficacy of repurposing antiviral drugs.
32462988 2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).
32406317 2020. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach.
32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.
32462970 2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
32456606 2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.
32462996 2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.
32476576 2020. Identification of potential natural inhibitors of SARS-CoV2 main protease by molecular docking and simulation studies.
32476574 2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.
32485061 2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.
32487869 2020. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
32433345 2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.
32511763 2020. Colchicine and COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32504739 2020. Interleukin-17: A potential therapeutic target in COVID-19.
32473010 2020. TPE-nAbs combination therapy for severe COVID-19.
32220033 2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).
32500858 2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases.
32511912 2020. COVID-19: Drug targets and potential treatments.
32469301 2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.
32380930 2020. Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19.
32472703 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.
32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.
32364561 2020. Randomized Clinical Trials and COVID-19: Managing Expectations.
32463427 2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.
32453363 2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.
32492105 2020. A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals.

32506195 2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
32438459 2020. Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence.
32463794 2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
32432810 2020. Letter: does vitamin D have a potential role against COVID-19?
32434272 2020. COVID-19Clinical trials: quality matters more than quantity.
32384798 2020. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.
32464736 2020. A simulation training course for family medicine residents in China managing COVID-19.
32505821 2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.
32485858 2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells.
32455629 2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.
32441299 2020. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
32398343 2020. Should azithromycin be used to treat COVID-19? A rapid review.
32464624 2020. Cytokine Blood Filtration Responses in COVID-19.
32454500 2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.
32453693 2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
32453692 2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.
32453687 2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
32503874 2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
32267762 2020. Research towards treating COVID-19.
32453903 2020. Efficacy of therapeutic plasma exchange in severe COVID-19 patients.
32438450 2020. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
32433778 2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
32442317 2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
32441783 2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
32424836 2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
32445484 2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.
32438446 2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
32441462 2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.
32511867 2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.
32418327 2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.
32449939 2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.
32420958 2020. Sofosbuvir as a potential option for the treatment of COVID-19.
32420947 2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).
32420936 2020. Treatments for COVID-19: emerging drugs against the coronavirus.
32425152 2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
32506621 2020. Drugs being investigated for children with COVID-19.
32468505 2020. Association between low vitamin D and COVID-19: don't forget the vitamin D binding protein.
32423954 2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.
32496210 2020. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.
32493028 2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.
32362105 2020. What information can I share with my patients about nutrition during COVID-19?
32510142 2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
32407491 2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.
32457999 2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19?
32403134 2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.
32430461 2020. Lack of efficacy of hydroxychloroquine in covid-19.
32503805 2020. Covid-19: Hydroxychloroquine was ineffective as postexposure prophylaxis, study finds.
32487664 2020. Covid-19: 146 researchers raise concerns over chloroquine study that halted WHO trial.
32269046 2020. Chloroquine and hydroxychloroquine in covid-19.
32345591 2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.
32303505 2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.
32407551 2020. Interrogation of the safety and efficacy of home-use light-based devices.
32480422 2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.
32480418 2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.
32415690 2020. Acute chloroquine poisoning: A comprehensive experimental toxicology assessment of the role of diazepam.
32498751 2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.
32498742 2020. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.
32429705 2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.
32436730 2020. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
32347743 2020. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
32412788 2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.
32501756 2020. Association of Hydroxychloroquine with QTc Interval in Patients with COVID-19.
32267732 2020. Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
32503806 2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.
32474583 2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.
32459003 2020. A role for retinoids in the treatment of COVID-19?
32474576 2020. Dose Optimization of Hydroxychloroquine for COVID-19: Do Blood Concentrations Matter?
32459832 2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.
32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.
32435791 2020. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients.
32427279 2020. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19.
32497168 2020. On setting expectations for a SARS-CoV-2 Vaccine.
32492123 2020. The Importance of Advancing SARS-CoV-2 Vaccines in Children.
32503801 2020. Does vitamin D deficiency increase the severity of COVID-19?
32341077 2020. Nutritional status and COVID-19: an opportunity for lasting change?
32303497 2020. Chloroquine and COVID-19 - a potential game changer?
32498131 2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.
32488861 2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19.
32350861 2020. COVID-19: A Defining Moment for Clinical Pharmacology?
32442315 2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.
32237918 2020. Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution.
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
32420691 2020. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.
32212378 2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.
32406927 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
32284037 2020. Perspective on the COVID-19 Coronavirus Outbreak.
32174284 2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.
32400323 2020. In vitro data of current therapies for SARS-CoV-2.
32427000 2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.
32436829 2020. Triazavirin - Potential inhibitor for 2019-nCoV Coronavirus M protease: A DFT study.
32487877 2020. Editorial: Challenges and Insights amidst the Covid-19 pandemic: Nutrition, the immune system and disease risk.
32487876 2020. Nutrition in times of Covid-19, how to trust the deluge of scientific information.
32479246 2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.
32416679 2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.
32394841 2020. COVID-19: An Update on Clinical Trials.
32282303 2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.
32475041 2020. Potential role of Anti-IL-17 in COVID-19 treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help?
32510734 2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.
32510719 2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.
32500633 2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.
32419517 2020. Emerging therapies for COVID-19 pneumonia.
32429703 2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
32419524 2020. Old and re-purposed drugs for the treatment of COVID-19.
32223349 2020. How could artificial intelligence aid in the fight against coronavirus?
32490453 2020. Luminescent silicon nanostructures and COVID-19.
32500928 2020. COVID-19 breakthroughs: separating fact from fiction.

32505474 2020. Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy.
32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
32505362 2020. Investigate Oral Zinc as a Prophylactic Treatment for Those at Risk for COVID-19.
32401673 2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.
32420751 2020. Evaluation of the Adjuvant Efficacy of Natural Herbal Medicine on COVID-19: A Retrospective Matched Case-Control Study.
32428965 2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.
32479158 2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
32437628 2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?
32476261 2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.
32458795 2020. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.
32446312 2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.
32503855 2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
32503853 2020. COVID-19 infection in a patient with FMF: does colchicine have a protective effect?
32327429 2020. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.
32295788 2020. Does hydroxychloroquine prevent the transmission of COVID-19?
32295786 2020. Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.
32345618 2020. Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev et al.
32340978 2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.
32321722 2020. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic.
32317316 2020. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
32317315 2020. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?

-rest-
32229705 2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections
32276453 2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
32325124 ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals
32312129 2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic
32336674 ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research
32356251 ä. Medical Toxicology and COVID-19: Our Role in a Pandemic
32243778 2020. Ensuring global access to COVID-19 vaccines
32247324 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings
32272857 2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks
C7190525 2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
32129977 2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases
29115746 2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies
29717819 2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens
C7194243 ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
32383008 ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic
32380052 2020. Granulocyte-targeted therapies for airway diseases
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro